NAD+
What Is NAD+? Structure, Cell Biology, Evidence and Regulatory Status
OS
· 11 min read
A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
On this page · 7 sections
NAD+ (nicotinamide adenine dinucleotide, oxidised form) is a coenzyme made by every living cell. It is a dinucleotide, not a peptide: two nucleotides joined through their phosphate groups, with no amino acids anywhere in it. Inside cells it carries electrons in energy metabolism and is consumed as a substrate by sirtuins, PARPs and CD38. The basic science is vast and settled at its core. The evidence about NAD+ supplied from outside a cell is much thinner: mostly cell and rodent work, plus two small human randomised trials, each from a single country. NAD+ has no authorisation as a medicine from Health Canada, the FDA or the EMA.

What is NAD+ made of?
Two nucleotides, linked by a pair of phosphates. One half is adenosine monophosphate, the same building block found in ATP and RNA. The other half is nicotinamide mononucleotide (NMN): a ribose sugar and a phosphate carrying nicotinamide, a form of vitamin B3. The nicotinamide ring is the working end. It accepts a hydride (two electrons and a proton) to become NADH and gives it up again to become NAD+.
| Property | NAD+ |
|---|---|
| Class | Dinucleotide coenzyme; not a peptide |
| Also called | Nicotinamide adenine dinucleotide; NAD; β-NAD+ |
| CAS number (PubChem) | 53-84-9 |
| Molecular formula (PubChem) | C21H27N7O14P2 |
| Molecular weight (PubChem) | About 663 g/mol |
| Reduced form | NADH |
| Evidence stage | Enormous cell and animal literature on the coenzyme inside cells; small, short human trials of NAD+ itself |
| Regulatory status | No Health Canada, FDA or EMA authorisation as a medicine found |
Because it is not a peptide, the usual peptide vocabulary does not apply to it: there is no sequence, no residues and no peptidase breakdown. The difference is set out in what are peptides.
How is NAD+ thought to work?
For an endogenous coenzyme, the question is less how it works than what cells use it for. Two jobs, which pull against each other.
Electron carrier. In glycolysis, the TCA pathway and fatty acid oxidation, NAD+ accepts electrons from fuels and becomes NADH; NADH hands them to the mitochondrial electron transport chain and becomes NAD+ again. Because the molecule is regenerated rather than used up, the NAD+/NADH ratio, not the total amount, is what tracks a cell's redox state (PMID 18020963). The mitochondrial side of this is covered in NAD+ and the mitochondrion.
Substrate for consuming enzymes. Three enzyme families break NAD+ apart and release nicotinamide:
| Enzyme family | What it does with NAD+ | Key finding |
|---|---|---|
| Sirtuins | Use it to remove acetyl groups from proteins | Yeast and mouse Sir2 shown to be NAD-dependent deacetylases (PMID 10693811) |
| PARPs | Use it to build poly(ADP-ribose) chains during DNA repair | Deleting PARP-1 in mice raised tissue NAD+ and SIRT1 activity (PMID 21459330) |
| CD38 | A membrane NADase that degrades NAD+ and NMN | Its expression and activity rose with age in mice, and it was required for the age-related NAD+ fall in that model (PMID 27304511) |
Since all three draw on one pool, they compete. That competition is the reason the sirtuin story and the DNA-repair story end up in the same papers.
The salvage pathway. Every consuming reaction leaves nicotinamide behind, and most NAD+ in mammals is remade from it. The enzyme NAMPT converts nicotinamide to NMN, and NMNAT enzymes convert NMN to NAD+. In mouse cells, Revollo and colleagues found NAMPT to be the rate-limiting step (PMID 15381699). Cells can also start from nicotinic acid (niacin), from nicotinamide riboside through NRK kinases (PMID 15137942), or from the amino acid tryptophan.
Does NAD+ supplied outside a cell get in?
This is the question the cell biology does not answer for you, and it is the most important one for anyone working with NAD+ as a reagent.
NAD+ is large and charged, and cells have no well-established transporter for it. In cultured human cells, Nikiforov and colleagues found that besides nicotinamide and nicotinic acid, only the nucleosides readily entered; nucleotides, NAD+ and NMN among them, were degraded outside the cell into permeable precursors, which the cell then rebuilt into NAD+ (PMID 21504897). Ratajczak and colleagues confirmed with isotope labelling that extracellular NMN is converted to nicotinamide riboside before uptake (PMID 27725675). Surface enzymes do the converting: CD73 turns NMN into nicotinamide riboside, while CD38 degrades it towards nicotinamide (PMID 23880765).
The practical consequence for reading this literature: an experiment that adds NAD+ to a culture or an animal is, to a large extent, an experiment with its breakdown products. A rise in intracellular NAD+ afterwards shows the salvage machinery worked, not that the intact molecule crossed the membrane. How the precursors compare is in NAD+ vs NMN vs NR.
What has NAD+ been studied for?
| Area | Evidence stage | What exists |
|---|---|---|
| Energy metabolism and redox | Textbook biochemistry | Settled role as an electron carrier |
| Sirtuin, PARP and CD38 biology | Cell and rodent | Large mechanistic literature |
| Age-related decline | Rodent; cross-sectional human tissue studies | Measured falls in several tissues, with method caveats |
| Heart failure | One human randomised trial | Imaging endpoint at one month |
| Sudden hearing loss | One small human randomised trial | Hearing thresholds over three months |
| Ageing outcomes in people | None | No trial of NAD+ itself with a lifespan or healthspan endpoint |
The age-decline finding is what turned NAD+ into a research target, and reviews describe it as seen in several model organisms and in human tissue (PMID 33353981). The human evidence is real but uneven. Massudi and colleagues measured pelvic skin removed during unrelated surgery from 49 people and found NAD+ correlated negatively with age, with PARP activity correlated positively (PMID 22848760). Clement and colleagues used mass spectrometry on plasma from adults aged 20 to 87 and found lower NAD+ with age but higher NADH (PMID 30124109). Zhu and colleagues used magnetic resonance in living human brain and reported lower NAD+ and a less oxidised redox ratio with age (PMID 25730862).
The caveats are as important as the finding. Those are three tissues, three methods and cross-sectional designs, so they show older people differ from younger ones, not how one person changes over time. Plasma NAD+ is extracellular and may not say much about any cell. McReynolds, Chellappa and Baur note that human data are limited and that the field lacks tools to measure NAD+ in specific cells and compartments (PMID 32097708). When the same group traced isotopes through aged mice, tissue NAD+ was down by a median of about 30%, but the rate of NAD+ production was maintained; the authors read the fall as relatively subtle and driven by consumption rather than failed synthesis (PMID 34559996). Measurement itself is a trap: NAD+ and NADH interconvert during sample handling, and Trammell and Brenner argue that HPLC with UV detection lacks the specificity for complex samples, which is why they developed an LC-MS assay (PMID 24688693). Why the instrument matters is covered in HPLC vs LC-MS.
Human trials of NAD+ itself are few and recent. Yu and colleagues randomised 180 adults with heart failure from ischaemic cardiomyopathy to NAD+ or placebo alongside standard therapy. The primary endpoint, left ventricular ejection fraction at one month, was about three percentage points higher in the NAD+ group; the clinical-event endpoints did not reach statistical significance (PMID 40954388). Gao and colleagues randomised 38 people with sudden sensorineural hearing loss to NAD+ plus standard treatment or standard treatment alone and reported larger gains in hearing thresholds (PMID 41035311). Each is one trial from one country, small or short, and unreplicated. An imaging measure is a surrogate, not a patient outcome, which is the point of surrogate endpoints explained.
Is NAD+ approved anywhere?
We found no authorisation of NAD+ as a medicine from Health Canada, the FDA or the EMA, for any indication. Related molecules sold as dietary supplements in some countries, such as NADH, NMN and nicotinamide riboside, sit in a different regulatory category; a supplement listing is not an assessment of efficacy. Status in Canada can be checked in the Drug Product Database, and the general framework is set out in peptides and Canadian law.
What is NAD+ commonly confused with?
NADH. The reduced form of the same molecule, carrying two extra electrons. The two interconvert constantly inside cells, but they are distinct compounds with their own literatures, and a finding about one is not a finding about the other.
NADP+ and NADPH. NAD+ with an extra phosphate. It serves mainly biosynthesis and antioxidant defence rather than energy production, and is a separate pool.
NMN and NR. Precursors, not NAD+. NMN is one enzymatic step away, NR two. Most human trials cited for "NAD+" are trials of these.
Niacin and nicotinamide. Forms of vitamin B3 that cells can build NAD+ from. Neither is NAD+.
A peptide. NAD+ is sold alongside research peptides, which leads people to assume it is one. It is a nucleotide-derived coenzyme.
L-Carnitine. Another non-peptide studied in mitochondrial energy research, but with a different job: it carries fatty acids into the mitochondrion rather than shuttling electrons. See what L-Carnitine is.
Supplied here for laboratory use: NAD+. Where a lot's certificate of analysis is published, it is linked from the product page. For laboratory research use only.
The findings above describe the compound in the cells, animals and people studied, not any laboratory reagent. Nothing here is medical, dosing, or therapeutic guidance.
Frequently asked questions
Is NAD+ a peptide? No. It is a dinucleotide: two nucleotides joined by phosphates. It contains no amino acids, and it is made by every living cell.
What is the difference between NAD+ and NADH? NAD+ is the oxidised form, which accepts electrons; NADH is the reduced form, which carries them to the mitochondrial electron transport chain. The ratio between them reflects a cell's redox state.
Do NAD+ levels really fall with age? Studies in mice and cross-sectional studies of human skin, plasma and brain report lower levels in older subjects. In aged mice the fall was modest, and the human studies used different tissues and methods, so the size of the decline in any given tissue is not settled.
Can cells take up NAD+ directly? The evidence in cultured human cells says mostly not: extracellular NAD+ is broken down to smaller precursors, which cells take up and rebuild. That is why experiments that add NAD+ from outside are hard to interpret.
Selected Research References
- Ying W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxidants & Redox Signaling. 2008;10(2):179-206. pubmed.ncbi.nlm.nih.gov/18020963
- Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795-800. pubmed.ncbi.nlm.nih.gov/10693811
- Bai P, Cantó C, Oudart H, et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metabolism. 2011;13(4):461-468. pubmed.ncbi.nlm.nih.gov/21459330
- Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism. 2016;23(6):1127-1139. pubmed.ncbi.nlm.nih.gov/27304511
- Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. Journal of Biological Chemistry. 2004;279(49):50754-50763. pubmed.ncbi.nlm.nih.gov/15381699
- Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell. 2004;117(4):495-502. pubmed.ncbi.nlm.nih.gov/15137942
- Nikiforov A, Dölle C, Niere M, Ziegler M. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. Journal of Biological Chemistry. 2011;286(24):21767-21778. pubmed.ncbi.nlm.nih.gov/21504897
- Ratajczak J, Joffraud M, Trammell SA, et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nature Communications. 2016;7:13103. pubmed.ncbi.nlm.nih.gov/27725675
- Grozio A, Sociali G, Sturla L, et al. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells. Journal of Biological Chemistry. 2013;288(36):25938-25949. pubmed.ncbi.nlm.nih.gov/23880765
- Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021;22(2):119-141. pubmed.ncbi.nlm.nih.gov/33353981
- Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357. pubmed.ncbi.nlm.nih.gov/22848760
- Clement J, Wong M, Poljak A, et al. The plasma NAD+ metabolome is dysregulated in "normal" aging. Rejuvenation Research. 2019;22(2):121-130. pubmed.ncbi.nlm.nih.gov/30124109
- Zhu XH, Lu M, Lee BY, et al. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proceedings of the National Academy of Sciences of the USA. 2015;112(9):2876-2881. pubmed.ncbi.nlm.nih.gov/25730862
- McReynolds MR, Chellappa K, Baur JA. Age-related NAD+ decline. Experimental Gerontology. 2020;134:110888. pubmed.ncbi.nlm.nih.gov/32097708
- McReynolds MR, Chellappa K, Chiles E, et al. NAD+ flux is maintained in aged mice despite lower tissue concentrations. Cell Systems. 2021;12(12):1160-1172. pubmed.ncbi.nlm.nih.gov/34559996
- Trammell SA, Brenner C. Targeted, LCMS-based metabolomics for quantitative measurement of NAD+ metabolites. Computational and Structural Biotechnology Journal. 2013;4:e201301012. pubmed.ncbi.nlm.nih.gov/24688693
- Yu X, Xu J, Cao J, et al. Effect of nicotinamide adenine dinucleotide on heart failure caused by ischemic cardiomyopathy: a randomized, placebo-controlled trial. American Journal of Cardiovascular Drugs. 2026;26(1):97-106. pubmed.ncbi.nlm.nih.gov/40954388
- Gao M, Guan Y, Yue X, et al. NAD+ enhanced on hearing recovery in sudden sensorineural hearing loss: randomized controlled trial. Laryngoscope. 2026;136(3):1204-1214. pubmed.ncbi.nlm.nih.gov/41035311
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
